Natural psilocybin has a new layer of legal protection in the United States. Filament Health, the Burnaby, British Columbia, drug developer behind the botanical psilocybin candidate PEX010, has received another U.S. patent covering how it pulls psychoactive compounds out of mushrooms and keeps them stable.
The patent, issued by the U.S. Patent and Trademark Office and announced Nov. 19 by Filament's parent company, Rhelion Life Sciences, is titled "Psychoactive Alkaloid Extraction and Composition with Inhibited Dephosphorylation." According to Rhelion, the grant brings Filament's portfolio to 79 issued patents across 13 patent families.
Psilocybin is a phosphorylated compound. Dephosphorylation is the chemical step in which psilocybin loses its phosphate group and becomes psilocin, the compound the body actually acts on. Psilocin is less stable outside the body, which is a challenge for anyone trying to make a consistent, shelf-stable drug from whole mushrooms. The new patent's title points to methods and compositions designed to slow that conversion during extraction and in the finished product.
Rhelion says Filament's patent estate covers extraction, purification, stabilization, standardized compositions and delivery, with issued patents in the United States, Canada, Australia, Israel, Mexico and Europe. The company describes it as the most extensive patent estate in natural psilocybin, a claim that reflects Rhelion's own view.
PEX010 is a standardized, GMP-manufactured botanical psilocybin drug candidate. Rather than synthesizing psilocybin in a lab, Filament extracts it from cultivated mushrooms and standardizes the result so every capsule has a consistent composition. Rhelion says PEX010 is offered in several fixed strengths from a single drug candidate, with a lower strength planned, so researchers can use the same material across different doses, studies and sites.
According to the company, PEX010 supplies or supports more than 80 academic and philanthropic research studies worldwide, along with compassionate access programs. Earlier this week, Filament said it had shipped PEX010 for a University of California, San Francisco study of psilocybin in older adults.
Rhelion, an Ontario-based company that trades in Canada, Germany and over the counter in the United States, completed its acquisition of Filament Health on April 30, 2026. That deal brought PEX010 and the patent portfolio under the Rhelion umbrella.
The patent arrives at a pivotal moment for psilocybin medicine. The two most advanced U.S. programs, from COMPASS Pathways and Usona Institute, both use synthetic psilocybin, and both companies have applications pending before the FDA. A first approval could come in 2027.
A handful of companies are betting there is room for naturally derived alternatives. Optimi Health Corp., another British Columbia company, this week outlined plans for a randomized Phase 2b depression trial of its own mushroom-derived psilocybin capsule. For businesses like Filament, patents on extraction and stabilization are a way to protect what makes a natural product consistent enough for clinical research and, eventually, regulators.
A patent protects a method or composition. It does not mean a product is approved, safe or effective for any condition. PEX010 remains an investigational drug candidate and is not approved by the FDA or Health Canada. Psilocybin is still a Schedule I controlled substance under U.S. federal law, and research supply moves only under the permits and authorizations that clinical studies require.
Rhelion also noted standard risks in its announcement, including the possibility that patents could be challenged, narrowed or designed around by competitors.